HyperMethod IBS Overview

  • Founded
  • 1991
  • Status
  • Acquired/​Merged
  • Employees
  • 11
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $9.8K
Latest Deal Amount

HyperMethod IBS General Information


Developer of educational software. The company develops software for e-learning, training and personnel assessment.

Contact Information

Formerly Known As
Ownership Status
Financing Status
Primary Industry
Educational Software
Other Industries
Education and Training Services (B2B)
Educational and Training Services (B2C)
Primary Office
  • ul. Gribakinykh, 25
  • Building 3, Business Center NEVOTON right wing, 2nd floor
  • Saint Petersburg, 192012
  • Russia
+7 8 (000) 000-00-00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

HyperMethod IBS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Jan-2013 $9.8K 000.00 Completed Generating Revenue
1. Merger/Acquisition 03-Mar-2008 Completed Generating Revenue
To view HyperMethod IBS’s complete valuation and funding history, request access »

HyperMethod IBS Executive Team (2)

Name Title Board Seat Contact Info
Yuri Perepelitsin Co-Founder & Chief Executive Officer
Krechman Dmitry Marketing Director
To view HyperMethod IBS’s complete executive team members history, request access »

HyperMethod IBS Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HyperMethod IBS Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
IBS (Russia) Corporation Majority 000 0000 000000 0
To view HyperMethod IBS’s complete investors history, request access »